Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 9009 results

  1. Excimer Laser Trabeculotomy (ELT) for glaucoma

    Awaiting development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

    In development Reference number: GID-TA11516 Expected publication date:  06 May 2027

    Technology appraisal guidance
    In development

  3. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    In development Reference number: GID-TA11743 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]

    Awaiting development Reference number: GID-TA11980 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]

    Awaiting development Reference number: GID-TA11979 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755]

    Awaiting development Reference number: GID-TA11974 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]

    Awaiting development Reference number: GID-TA11969 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]

    Awaiting development Reference number: GID-TA11962 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma

    In development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    In development

  11. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death

    In development Reference number: GID-IPG10437 Expected publication date: TBC

    Interventional procedures guidance
    In development

  13. Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]

    Awaiting development Reference number: GID-TA11954 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)

    In development Reference number: GID-NG10469 Expected publication date: TBC

    NICE guideline
    In development

  15. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development